Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase NA 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER 3NIH 2

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 5Other hematologic neoplasm 3Genitourinary 3Gastrointestinal 2CNS 2Thoracic 1Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Prostatic Neoplasms 2Carcinoma, Renal Cell 1

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 151Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Protein Subunit Vaccines × Genitourinary × Clear all
NCT00694551 2019-10-04

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
29 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

NCT02429440 2017-08-17

UroRCC

University Hospital Tuebingen

Phase 1/2 Unknown
40 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT02452307 2017-08-17

Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy

University Hospital Tuebingen

Phase 1/2 Unknown
36 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡